FDA consults on co-development of unmarketed drugs for use in combination
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued for consultation draft guidance to help pharmaceutical companies in the co-development of two or more previously unmarketed drugs to be used in combination to treat a disease or a condition1-3.